The Language of Health Care Rationing
by Capitol ConfidentialThe Food and Drug Administration (FDA) is moving to “de-label” Avastin, the late-stage cancer drug for breast cancer patients. If successful, the FDA would allow Medicare and private insurance to deny coverage for the drug – even for patients who have relied on the drug to live.
The FDA has denied that the cost of the drug played a role in their decision but the evidence is mounting that is not the case. During initial consideration of the decision an FDA advisor specifically cited the cost of the drug as the reason for revocation. The drug costs $80,000 a year and allowing Medicare to deny coverage for the cost would “reduce the cost of health care,” as President Obama has demanded.
The FDA and their supporters deny cost is the basis of the decision. George Soros’ Media Matters denounced the rationing claim proclaiming that the drug does not “does not significantly prolong life.”
Significantly? Is six months, the average time an Avastin patient gets in extended life, “significant”? Is one year? What about the cases of the “super responders,” the women like Erin Howarth, who have taken Avastin for years and credit the drug for saving their life?







Subscribe via RSS
Got a Tip?